Opus Genetics Files 8-K/A Amendment
Ticker: IRD · Form: 8-K/A · Filed: Jan 7, 2025 · CIK: 1228627
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Opus Genetics filed an amendment to an 8-K, correcting/adding info from Oct 22nd.
AI Summary
Opus Genetics, Inc. filed an 8-K/A on January 7, 2025, to amend a previous filing regarding financial statements and exhibits. The original event date reported was October 22, 2024. The company, formerly known as Ocuphire Pharma, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing is an amendment to a previous report, indicating a correction or addition to previously disclosed information, which could be material for investors.
Risk Assessment
Risk Level: low — This is a routine amendment filing for financial statements and exhibits, not indicating new material events or significant financial changes.
Key Numbers
- 001-34079 — SEC File Number (Identifies the company's filings with the SEC.)
- 11-3516358 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former company name
- 20250107 (date) — Filing date
- 20241022 (date) — Earliest event reported date
- 2834 (number) — Standard Industrial Classification (SIC) code for Pharmaceutical Preparations
FAQ
What specific financial statements or exhibits are being amended in this 8-K/A filing?
The filing indicates it is amending Item 9.01 (Financial Statements and Exhibits) of a previous report, but the specific details of the amendment are not provided in this header information.
What was the original event date that this 8-K/A filing is amending?
The earliest event reported date that this 8-K/A filing is amending is October 22, 2024.
What is the primary business of Opus Genetics, Inc. according to its SIC code?
Opus Genetics, Inc. is classified under SIC code 2834, which corresponds to Pharmaceutical Preparations.
When was Opus Genetics, Inc. formerly known as Ocuphire Pharma, Inc.?
The filing indicates that the former company name was Ocuphire Pharma, Inc. and the date of the name change was November 9, 2020.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive offices are located at 8 Davis Drive, Suite 220, Durham, NC 27709.
Filing Stats: 1,003 words · 4 min read · ~3 pages · Grade level 13.9 · Accepted 2025-01-07 17:10:16
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
Filing Documents
- ef20041180_8ka.htm (8-K/A) — 35KB
- ef20041180_ex23-1.htm (EX-23.1) — 11KB
- ef20041180_ex99-1.htm (EX-99.1) — 457KB
- ef20041180_ex99-2.htm (EX-99.2) — 376KB
- ef20041180_ex99-3.htm (EX-99.3) — 388KB
- 0001140361-25-000467.txt ( ) — 1517KB
- ird-20241022.xsd (EX-101.SCH) — 4KB
- ird-20241022_lab.xml (EX-101.LAB) — 21KB
- ird-20241022_pre.xml (EX-101.PRE) — 16KB
- ef20041180_8ka_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The audited balance sheet of the Acquired Company as of December 31, 2023 and the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders' deficit and cash flows for the year ended December 31, 2023, including all notes thereto, are filed herewith as Exhibit 99.1 and incorporated by reference herein. The unaudited balance sheet of the Acquired Company as of September 30, 2024 and the related statements of operations and comprehensive loss, changes in convertible preferred stock and stockholders' deficit and cash flows for the nine months ended September 30, 2024, including all notes thereto, are filed herewith as Exhibit 99.2 and incorporated by reference herein. (b) Pro Forma Financial Information The unaudited pro forma combined condensed balance sheet of the Company as of September 30, 2024 and the unaudited pro forma combined condensed reference herein. (d) Exhibits Exhibit Description 23.1 Consent of Ernst & Young LLP, independent accounting firm for the Acquired Company 99.1 Audited financial statements of the Acquired Company as of and for the year ended December 31, 2023 99.2 Unaudited financial statements of the Acquired Company as of and for the nine months ended September 30, 2024 99.3 Unaudited pro forma combined condensed financial information 104 Cover page interactive data file (formatted as inline XBRL) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OPUS GENETICS, INC. Date: January 7, 2025 By: /s/